Established in Bethesda in 2019 as the first global subsidiary of a Japanese pharmaceutical company founded in Tokyo in 2003, Nobelpharma America develops and brings medicines and medical devices to U.S. patients with rare or underserved conditions. Its purpose is to pursue treatments that larger companies may overlook because few patients are affected or existing options are limited. The company works with worldwide experts to move essential therapies from development toward patients, caregivers, and health care providers.